SCHEMBL2988403

SCHEMBL2988403

CC(NC(=O)c1cc(Oc2ccc(F)cc2)ccc1CCCC(=O)O)c1cccc2ccccc12

nearest known ligand 0.62

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
PPARG P37231 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2988400 1.00 MEN1 (0.47) MEN1KMT2APPARG
SCHEMBL2979406 0.94
SCHEMBL2979405 0.94
SCHEMBL2974554 0.94 PPARG (0.45) PPARG
SCHEMBL2974550 0.94 PPARG (0.45) PPARG
SCHEMBL2983655 0.92 MEN1 (0.50) MEN1KMT2A
SCHEMBL2983659 0.92 MEN1 (0.50) MEN1KMT2A
SCHEMBL2980964 0.91 MEN1 (0.48) MEN1KMT2APPARG
SCHEMBL2980961 0.91 MEN1 (0.48) MEN1KMT2APPARG
SCHEMBL2978567 0.91

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101284773-A Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient ONO PHARMACEUTICAL CO (JP) 2008-10-15 CN claimed
US-20060258728-A1 Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2006-11-16 US claimed
CN-1551866-A Carboxylic acid derivative compounds and drugs containing these compounds as active ingredient СҰҩƷ��ҵ��ʽ���� 2004-12-01 CN claimed
EP-1431267-A1 CARBOXYLIC ACID DERIVATIVE COMPOUNDS AND DRUGS COMPRISING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-06-23 EP claimed
US-7786161-B2 Carboxylic acid derivatives and pharmaceutical agent comprising the same as active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2010-08-31 US disclosed
US-20090318703-A1 CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD (JP) 2009-12-24 US disclosed
US-7491748-B2 Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2009-02-17 US disclosed
CN-101284773-A Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient ONO PHARMACEUTICAL CO (JP) 2008-10-15 CN disclosed
US-20060258728-A1 Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2006-11-16 US disclosed
CN-1551866-A Carboxylic acid derivative compounds and drugs containing these compounds as active ingredient СҰҩƷ��ҵ��ʽ���� 2004-12-01 CN disclosed
EP-1431267-A1 CARBOXYLIC ACID DERIVATIVE COMPOUNDS AND DRUGS COMPRISING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-06-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318703-A1 CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT PTGER2, PTGER4, PTGER1 MEN1 3705/4885KMT2A 2549/4885PPARG 1009/4885
US-20060258728-A1 Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient PTGER2, PTGER4, PTGER1 MEN1 3489/4885KMT2A 2400/4885PPARG 1411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.